Cosmo Pharmaceuticals Announces Amendment of its Investment Agreement with Acacia
Cosmo Pharmaceuticals N.V. today announced that, on 14 December 2020, Acacia Pharma Group plc (“Acacia”) (EURONEXT: ACPH) and Cosmo entered into an amendment agreement (the “Amendment Agreement”) being an amendment to the Investment Agreement between the parties dated 10 January 2020, pursuant to which Acacia and Cosmo agreed that, in exchange for Cosmo prioritising the packaging and labelling production run for BYFAVOTM for supply in the US, Acacia shall make the EUR 5 million payment due on the first commercial sale of BYFAVOTM in advance of the first commercial sale of BYFAVOTM and by no later than 31 December 2020.